The FDA could offset drug price spikes or shortages by allowing reciprocal approvals for certain generic drugs with limited competition, according to joint research from Johns Hopkins, Yale, Harvard and the Council on Foreign Relations, published in BMJ.
Source: Drug Industry Daily